Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $37.67M
• Dividend Yield: N/A
• Average Volume (3M): 62.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: 1.19%
• EPS Growth: 61.65%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -2.77
• Shares Outstanding: 8,639,904
• 10 Day Avg. Volume: 39,007
• 30 Day Avg. Volume: 62,132
• PEG Ratio: -0.40
• Price to Book (P/B): -2.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.30
• Enterprise Value/Market Cap: 2.37
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 0.65
• Enterprise Value/Ebitda: -0.46
• 1Y Price Target: $23.25
• Price Target Upside: 404.34% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 42 Neutral
• Price Target: $4.50 ▼(-2.39%Downside)

Karyopharm Therapeutics' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, persistent losses, and high leverage. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. While the earnings call provided some positive updates on clinical trials, financial challenges remain a significant concern.

Positive Factors

FDA Fast Track Designation

Xpovio previously received FDA Fast Track Designation for the treatment of patients with myelofibrosis.

Global Expansion

Reimbursement approvals were received in the UK, Italy, France, China, and South Korea, with additional global launches and reimbursement approvals expected.

Revenue Growth Potential

Karyopharm estimates a peak revenue opportunity of $1 billion for Xpovio in myelofibrosis.

Negative Factors

Operating Expenses Concern

Analysts remain on the sidelines, awaiting more durable growth trends on Xpovio sales and convincing evidence that sales growth will not be overshadowed by existing operating expenses.

Revenue Decline

KPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter.

Rising Competition

Challenges of rising competition and higher gross-to-net adjustments were noted as headwinds to sales.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the sale of its pharmaceutical products, particularly selinexor, which is marketed under the brand name XPOVIO. The company earns revenue from product sales in the United States and collaborates with international partners for distribution outside the U.S. Additionally, Karyopharm engages in licensing agreements and strategic partnerships with other pharmaceutical companies to expand its market reach and support drug development, which can include upfront payments, milestone payments, and royalties on sales. The company also invests in research and development to expand its pipeline of investigational drugs, aiming to bring additional products to market and diversify its revenue streams.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, consistent losses, negative equity, and cash flow issues. The high level of debt and negative margins present substantial risks, while reliance on external financing highlights the company's need for careful financial management to sustain operations.

Income Statement

Karyopharm Therapeutics has experienced a significant decline in revenue over the past few years, with the most recent year showing a slight decrease in revenue from $146.0 million to $145.2 million. The company consistently reports negative net income, with a net profit margin of -52.6% for the latest year, indicating challenges in achieving profitability. Additionally, the EBIT and EBITDA margins are negative, reflecting operating inefficiencies and high costs relative to revenue.

Balance Sheet

The company faces a challenging financial structure with negative stockholders' equity, indicating liabilities far exceed assets, and a debt-to-equity ratio that is not meaningful due to negative equity. The equity ratio is also negative, suggesting very high financial risk. There is a high level of total debt, which could pose significant risks if not managed properly.

Cash Flow

Karyopharm's cash flow from operations is negative, and free cash flow is also negative, which indicates difficulties in generating cash to cover operations and investments. However, there is a noticeable increase in financing cash flow, suggesting reliance on external funding. The free cash flow growth rate is negative, further emphasizing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	142.13M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	136.64M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-40.54M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-62.52M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	325.80M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	260.38M	108.71M	191.44M	277.97M	228.62M	273.45M
Total Debt	178.59M	194.52M	177.02M	172.98M	169.29M	117.93M
Total Liabilities	370.97M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-45.17M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-122.69M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-122.75M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	88.82M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	41.65M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Neutral. The current price of 4.61 is above the 20-day moving average (MA) of 4.41, below the 50-day MA of 5.08, and below the 200-day MA of 8.66, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 51.09 is Neutral, neither overbought nor oversold. The STOCH value of 48.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	AU$2.47B	4.40	-64.25%	2.83%	36.51%	13.14%
CNTB	49 Neutral	$58.67M	―	-58.89%	―	―	―
XFOR	44 Neutral	$11.46M	0.88	121.75%	―	―	―
KPTI	42 Neutral	$37.67M	―	41.08%	―	1.19%	61.65%
PEPG	40 Underperform	$35.67M	―	-75.45%	―	―	14.06%
HOWL	39 Underperform	$48.01M	―	-82.81%	―	-92.95%	-50.02%
CAMP		$27.22M	―		―	―	―

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment

At the 2025 Annual Meeting of Stockholders held on May 28, Karyopharm Therapeutics Inc. announced that its stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available by 450,000. Additionally, Garen G. Bohlin and Zhen Su were elected as Class III directors for a three-year term. The stockholders also approved the compensation of the company’s named executive officers and recommended annual advisory votes on this compensation. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.